Question-and-Answer Session
Operator
(Operator Instructions). Our first question comes from Arnie Ursaner from CJS Securities. Your line is now open.
Arnie Ursaner
Dennis, congratulations.
Dennis Allingham
Thanks, Arnie. Good morning.
Arnie Ursaner
First thing as it relates to Warburg, you mentioned they owned Keystone Dental where they've got a technology that you believe would be very complimentary to what you are doing. Could you expand a little bit more on that please?
Dennis Allingham
Yeah. My understanding is that Keystone is in the process of developing a Single-Stage Implant System, which of course, we do offer one today, but I've also made comments in other calls that our product offering on the Single Stage side, which we introduced back in 1999 really needs to refreshed. Keystone, I understand also has a line of regenerative products that I think would be complimentary to the line of regenerative products that we sell. So, I believe there is some synergies there between the two businesses.
Arnie Ursaner
My other question is, in your prepared remarks you mentioned that you as a company had looked at some other strategies to enhance shareholder value and I am sure they’ll all be covered in detail in the proxy when it becomes available. But can you give us a little bit of an understanding of what some of the other strategies you had looked at were and perhaps expand on that a little?
Dennis Allingham
Sure, I think the key thing is and, of course, this has been the $64 question at virtually a number of calls, what are you going do with the cash? And so the very obvious one is, should we pay a dividend? And we determined not to. Should we look at a stock buyback? And that to me always and certainly our Board considered it but has short term improvement but perhaps not long term.
And I think the thing that we explored was and it's more really by myself and our management team is what is out there that we could acquire to really truly help drive the growth of either of our business segments, either the Dental or the Hyaluronan.
And the difficult part was there really wasn't anything that we could see at least that would fit. And I think what we came back to is certainly we believe we've set forth the right strategies for the long-term growth of the company. We felt that we could invest cash into the growth of both sides of the business.
- To read the full transcript on Seeking Alpha, click here »
